Home Editorial Page 10

Editorial

Pivotal Trial In Relapsed And Refractory Hodgkin Lymphoma Shows Positive Results With Brentuximab Vedotin...

Results of a pivotal clinical trial with of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30...

FDA Rejects Accelerated Approval For T-DM1, Global Regulatory Submission Expected In Mid 2012

Earlier today the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for...

Investigational Antibody-Drug Conjugate, Shows Encouraging Results in Women With Highly Advanced HER2-positive Breast Cancer

Results of a Phase II study of trastuzumab (Herceptin®, Genentech) in combination with DM1 (T-DM1), an investigational HER2 antibody-drug...